These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 36254767)

  • 1. Metabolic syndrome, hepatic fibrosis, and steatosis diagnosed by liver stiffness measurement and controlled attenuation parameter after liver transplantation: the impact on long-term survival.
    Eshraghian A; Fattahi MR; Taghavi A; Shamsaeefar A; Mansoorian M; Kazemi K; Nikeghbalian S; Malek-Hosseini SA
    Expert Rev Gastroenterol Hepatol; 2022 Oct; 16(10):1003-1009. PubMed ID: 36254767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study.
    Cardoso CRL; Villela-Nogueira CA; Leite NC; Salles GF
    Cardiovasc Diabetol; 2021 Sep; 20(1):193. PubMed ID: 34560854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
    Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
    Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of Controlled Attenuation Parameter and Liver Stiffness Measurement for the Identification of Extended-criteria Donors and Risk-assessment in Liver Transplantation.
    Duarte-Rojo A; Heimbach JK; Borja-Cacho D; Barone GW; Shaheen MF; Lamps LW; Graham RP; Tan EK; Concepcion W; Kim WR
    Transplantation; 2022 Feb; 106(2):318-327. PubMed ID: 33675319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic Performance of Vibration-Controlled Transient Elastography in Liver Transplant Recipients.
    Siddiqui MS; Idowu MO; Stromberg K; Sima A; Lee E; Patel S; Ghaus S; Driscoll C; Sterling RK; John B; Bhati CS
    Clin Gastroenterol Hepatol; 2021 Feb; 19(2):367-374. PubMed ID: 32272251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study.
    Demir M; Deyneli O; Yılmaz Y
    Turk J Gastroenterol; 2019 Mar; 30(3):266-270. PubMed ID: 30411703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis.
    Sagara M; Iijima T; Kase M; Kato K; Sakurai S; Tomaru T; Jojima T; Usui I; Aso Y
    J Diabetes Complications; 2021 May; 35(5):107885. PubMed ID: 33602617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Steatosis and Fibrosis in Liver Transplant Recipients Using Controlled Attenuation Parameter and Liver Stiffness Measurements.
    Mikolasevic I; Hauser G; Mijic M; Domislovic V; Radic-Kristo D; Krznaric Z; Razov-Radas M; Pavic T; Matasin M; Filipec Kanizaj T
    Can J Gastroenterol Hepatol; 2021; 2021():6657047. PubMed ID: 33628759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moderate to severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis.
    Shen F; Mi YQ; Xu L; Liu YG; Wang XY; Pan Q; Zhang RN; Hu XQ; Xu LM; Fan JG
    Aliment Pharmacol Ther; 2019 Jul; 50(1):93-102. PubMed ID: 31094016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis.
    Lee JI; Lee HW; Lee KS
    World J Gastroenterol; 2019 Sep; 25(33):4959-4969. PubMed ID: 31543686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Magnetic Resonance Elastography and Transient Elastography for Liver Fibrosis and Steatosis Assessments in the Liver Transplant Setting.
    Melekoglu Ellik Z; Idilman IS; Kartal A; Balaban Y; Elhan AH; Karcaaltincaba M; Ozkan H; Idilman R
    Turk J Gastroenterol; 2022 Feb; 33(2):153-160. PubMed ID: 35238782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan
    Oeda S; Takahashi H; Imajo K; Seko Y; Ogawa Y; Moriguchi M; Yoneda M; Anzai K; Aishima S; Kage M; Itoh Y; Nakajima A; Eguchi Y
    J Gastroenterol; 2020 Apr; 55(4):428-440. PubMed ID: 31654131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive characterization of graft steatosis after liver transplantation.
    Karlas T; Kollmeier J; Böhm S; Müller J; Kovacs P; Tröltzsch M; Weimann A; Bartels M; Rosendahl J; Mössner J; Berg T; Keim V; Wiegand J
    Scand J Gastroenterol; 2015 Feb; 50(2):224-32. PubMed ID: 25429378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Applicability and Results of Liver Stiffness Measurement and Controlled Attenuation Parameter Using XL Probe for Metabolic-Associated Fatty Liver Disease in Candidates to Bariatric Surgery. A Single-Center Observational Study.
    Wan T; Köhn N; Kröll D; Berzigotti A
    Obes Surg; 2021 Feb; 31(2):702-711. PubMed ID: 32959331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.
    Imajo K; Kessoku T; Honda Y; Tomeno W; Ogawa Y; Mawatari H; Fujita K; Yoneda M; Taguri M; Hyogo H; Sumida Y; Ono M; Eguchi Y; Inoue T; Yamanaka T; Wada K; Saito S; Nakajima A
    Gastroenterology; 2016 Mar; 150(3):626-637.e7. PubMed ID: 26677985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography.
    Myers RP; Pollett A; Kirsch R; Pomier-Layrargues G; Beaton M; Levstik M; Duarte-Rojo A; Wong D; Crotty P; Elkashab M
    Liver Int; 2012 Jul; 32(6):902-10. PubMed ID: 22435761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How Good Are Controlled Attenuation Parameter Scores from Fibroscan to Assess Steatosis, NASH, and Fibrosis?
    Trowell J; Alukal J; Zhang T; Liu L; Maheshwari A; Yoo HY; Thuluvath PJ
    Dig Dis Sci; 2021 Apr; 66(4):1297-1305. PubMed ID: 32337667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential impact of screening for fatty liver disease by transient elastography with liver stiffness and controlled attenuation parameter measurements: a pilot study.
    Peiseler M; Creutzfeldt A; Cassens I; Glaubke C; Kroll C; Lohse AW; Weiler-Normann C
    Z Gastroenterol; 2017 Aug; 55(8):754-760. PubMed ID: 28655068
    [No Abstract]   [Full Text] [Related]  

  • 20. Hepatic steatosis leads to overestimation of liver stiffness measurement in both chronic hepatitis B and metabolic-associated fatty liver disease patients.
    Liu J; Ma Y; Han P; Wang J; Liu YG; Shi RF; Li J
    Clin Res Hepatol Gastroenterol; 2022 Oct; 46(8):101957. PubMed ID: 35609821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.